Schizophrenia, obesity and pharmacotherapy-associated weight gain;Schizofrenia, obesità e incremento ponderale associato alla farmacoterapia

Clinica Terapeutica

Volumn 159, Issue 5, 2008, Pages 299-306

  Carpiniello, Bernardo ^a,b   Corda, E ^a   Maccioni, R ^a   Pinna, F ^a  

^a DEPARTMENT OF RADIOLOGY   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Abdominal obesity; Antipsychotics; BMI; Obesity; Schizophrenia

Indexed keywords

ABDOMINAL OBESITY; ADULT; ARTICLE; BODY MASS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; SCHIZOPHRENIA; WAIST CIRCUMFERENCE; WEIGHT GAIN;

ABDOMINAL FAT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BODY HEIGHT; BODY MASS INDEX; BODY WEIGHT; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; OBESITY; PREVALENCE; SCHIZOPHRENIA; WAIST CIRCUMFERENCE; WAIST-HIP RATIO; WEIGHT GAIN;

EID: 56249093457     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. ISTAT. Condizioni di salute, fattori di rischio e ricorso ai servizi sanitari - anno 2005 - nota per la stampa. Epub 2 marzo 2007
2. Kuerzmaski RJ, Flegal KM, Troiano RP. Varying body mass index cutoff points to describe overweight prevalence among US adults: NHANES III (1988-1994). Obes Res 1997; 5:542-8
3. Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry 2004; 65 Suppl 18:13-26
4. Allison DB, Fontaine KR, Mentore JR, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999; 60(4):215-20
5. Bobes J, Arango C, Aranda P, et al. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res 2007; 90(1-3):162-73. Epub 2006
6. Meyer JM, A retrospective comparison of weight, lipid and glucose changes between risperidone and olanzapine-treated inpatients:metabolic outcomes after 1-year. J Clin Psych 2002; 63:425-33
7. Wirshing DA, Meyer JM. Obesity in patients with schizophrenia. In: Meyer JM, Nasrallah H (Eds). Medical Illness and Schizophrenia. Am Psychiatric Press Inc, Washington DC, 2003; 39-58
8. Conley RR, Shim JC, Kelly DL, et al. Cardiovascular disease in relation to weight in deceased persons with schizophrenia. Compr Psychiatry 2005; 46:460-7
9. Bernstein JG. Induction of obesity by psychotropic drugs. Ann NY Acad Sci 1987; 499:203-15
10. Fakhoury WKH, Wright D, Wallace M. Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helping. Int Clin Psychopharmacol 2001; 16:153-62
11. Newcomer JW. Metabolic Disturbances associated with antipsychotic use. J Clin Psychiatry 2001; 62(suppl 27):-4
12. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19(suppl 1):1-93
13. Barnes TR, Paton C, Cavanagh MR, et al. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr Bull 2007; May 4 (Epub ahead of print)
14. Jones LE, Carney CP. Increased risk for metabolic syndrome in persons seeking care for mental disorders. Ann Clin Psychiatry 2006; 18(3):149-55
15. Basu R, Brar JR, Chengappa KN, et al. The prevalence of the metabolic syndrome in patients with schizoaffective disorder-bipolar subtype. Bipolar Disord 2004; 6(4):314-8
16. Suvisaari JM, Saarni SI, Perälä J, et al. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psich 2007; 68 (7):1045-55
17. Brown S. Excess mortality of schizophrenia. A meta-analysis. Brit J Psychiatry 1997; 171:502-8
18. Osservatorio Epidemiologico Cardiovascolare Italiano. Ital Heart J 2004; 5(suppl 3):49S-92S
19. Susce MT, Vullanueva N, Diaz FJ, et al. Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. J Clin Psichiatry 2005; 66(2):167-73
20. Coodin S. Body mass index in persons with schizophrenia. Can J Psychiatry 2001; 46 (6):549-55
21. Mokdad AH, Ford ES, Bowman BA, et al. prevalence of obesity, diabetes and obesity related health risk factors, 2001. JAMA 2003; 289:76-9
22. Flegal KM, Carrol MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002; 288:1723-7
23. Homel P, Casey D, Allison DB. Changes in body mass index for individuals with and without schizophrenia, 1987-1996. Schizophr Res 2002; 55:277-84
24. Kato MM, Currier MB, Villaverde O, et al. The relation between body fat distribution and cardiovascular risk factors in patients with schizophrenia: a cross-sectional pilot study. Prim Care Companion. J Clin Psychiatry 2005; 7(3):115-8; quiz 119-20
25. Mc Evoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80:19-32
26. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60:358-63
27. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62(suppl 7):22-31
28. American Diabetes Association and American Psychiatric Association,Consensus development conference on antipsychotic drugs and obesity and diabetes, Diabetes Care, 2004; 27:596-601
29. Barnes T, Paton C, Cavanagh M, et al, A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophrenia Bull 2007; 33:1397-403